Life Tech Wins $870K CIRM Grant To Develop hESC Model of ALS

Life Technologies, the company formed from the merger of Invitrogen and Applied Biosystems, said its goal is to create a proof-of-principle model to better understand the pathogenesis of ALS in human tissues by using homologous recombination to establish in vitro disease models in hESCs.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.